|
 The study tested Lynparza in patients as an add-on to an already
existing standard of care, bevacizumab, and was compared to a group
of patients given bevacizumab alone.
The treatment showed a statistically significant and clinically
meaningful improvement in progression-free survival in women with
newly diagnosed advanced ovarian cancer, the companies said.
Lynparza added to bevacizumab reduced the risk of disease
progression or death by 41% in the overall trial population.
The combination also improved progression-free survival to a median
of 22.1 months compared to 16.6 months for those treated with
bevacizumab alone, the companies said.
[to top of second column] |
The treatment, which is being jointly developed and commercialized
by AstraZeneca and Merck, is approved for the treatment of advanced
ovarian cancer and metastatic breast cancer and has been used to
treat over 25,000 patients worldwide.
The American Cancer Society expects about 22,530 women to be newly
diagnosed with ovarian cancer in 2019.
(Reporting by Aakash Jagadeesh Babu in Bengaluru; Editing by Bernard
Orr)
[© 2019 Thomson Reuters. All rights
reserved.] Copyright 2019 Reuters. All rights reserved. This material may not be published,
broadcast, rewritten or redistributed.
Thompson Reuters is solely responsible for this content. |
